NewGenIvf (NIVF) awards CMO 56,851 low-priced share options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NewGenIvf Group Ltd reported that Chief Marketing Officer Fong Hei Yue Tina received a grant of stock options to acquire 56,851 Class B Ordinary Shares. The options carry an exercise price of US$0.0001 per share and were granted under the company’s 2024 Share Incentive Plan.

The award vests over time: 5,685 options on June 4, 2026, 1,462 options on the 4th day of each month from July 4, 2026 through April 4, 2029, and 1,458 options on May 4, 2029. The options expire on May 4, 2033, and following this grant she holds 56,890 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fong Hei Yue Tina

Role Chief Marketing Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	56,851	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 56,890 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 56,851 options Exercise price: US$0.0001 per share Underlying shares: 56,851 Class B Ordinary Shares +5 more

8 metrics

Stock options granted 56,851 options Grant to CMO on May 4, 2026

Exercise price US$0.0001 per share Exercise price for granted options

Underlying shares 56,851 Class B Ordinary Shares Shares issuable upon option exercise

First vesting tranche 5,685 options Vest on June 4, 2026

Monthly vesting tranches 1,462 options per month From July 4, 2026 to April 4, 2029

Final vesting tranche 1,458 options Vest on May 4, 2029

Option expiration May 4, 2033 Expiration date for granted options

Options held after grant 56,890 options Total options following transaction

Key Terms

2024 Share Incentive Plan, Employee Stock Option Agreement, Class B Ordinary Shares, stock options

4 terms

Employee Stock Option Agreement financial

"and the Employee Stock Option Agreement, dated 4 May 2026, between the Issuer and the Reporting Person"

Class B Ordinary Shares financial

"stock options to acquire 56,851 Class B Ordinary Shares of the Issuer"

Class B ordinary shares are a type of ownership stake in a company that typically come with different voting rights or privileges compared to other share classes. For investors, they represent a way to hold part of the company’s value and influence its decisions, often with fewer voting rights than Class A shares. Understanding these shares helps investors assess their level of control and potential returns within a company.

stock options financial

"Reflects the grant of stock options to acquire 56,851 Class B Ordinary Shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Form 4 Insider Transactions: What Each Field Means →

05/06/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fong Hei Yue Tina

(Last)

(First)

(Middle)

C/O 1/F, PIER 2, CENTRAL

(Street)

HONG KONG

(City)

(State)

(Zip)

HONG KONG

(Country)

2. Issuer Name and Ticker or Trading Symbol
NewGenIvf Group Ltd [ NIVF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Marketing Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$0.0001	05/04/2026		A		56,851		⁽¹⁾	05/04/2033	Class B Ordinary Shares	56,851	$0	56,890	D

Explanation of Responses:

1. Reflects the grant of stock options to acquire 56,851 Class B Ordinary Shares of the Issuer at an exercise price of US$0.0001 per share, made pursuant to the Issuer's 2024 Share Incentive Plan and the Employee Stock Option Agreement, dated 4 May 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options vest as follows: 5,685 options on 4 June 2026 (First Tranche); 1,462 options on the 4th day of each month from 4 July 2026 through 4 April 2029 (34 monthly tranches); and 1,458 options on 4 May 2029 (Final Tranche). The options expire on 4 May 2033, subject to earlier termination as provided in the Option Agreement and the Plan.

	/s/ Hei Yue Tina Fong	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NewGenIvf (NIVF) report for Fong Hei Yue Tina?

NewGenIvf reported a compensation-related grant to Chief Marketing Officer Fong Hei Yue Tina of 56,851 stock options. These options allow her to acquire Class B Ordinary Shares at a very low exercise price, reflecting a long-term equity incentive rather than an open-market purchase.

How many NewGenIvf (NIVF) options were granted and at what exercise price?

The filing shows a grant of 56,851 stock options, each exercisable into one Class B Ordinary Share at an exercise price of US$0.0001 per share. This nominal price is typical for employee stock options issued as part of an incentive compensation plan.

What is the vesting schedule for the NewGenIvf (NIVF) stock options granted?

The options vest in tranches: 5,685 options on June 4, 2026, then 1,462 options on the 4th day of each month from July 4, 2026 through April 4, 2029, and a final 1,458 options on May 4, 2029. This creates a multi-year vesting timeline.

When do the NewGenIvf (NIVF) options granted to the CMO expire?

The granted stock options expire on May 4, 2033, subject to earlier termination under the Option Agreement and the company’s 2024 Share Incentive Plan. This long-dated expiration gives the executive an extended period to potentially exercise the options once vested.

How many NewGenIvf (NIVF) options does the reporting person hold after this grant?

After the reported grant, the Form 4 shows total holdings of 56,890 stock options by the reporting person. This figure reflects her direct derivative position in the company’s equity as of the transaction date, combining the new grant with any prior option holdings.

Under what plan were the NewGenIvf (NIVF) options granted to the CMO?

The filing states that the options were granted under NewGenIvf’s 2024 Share Incentive Plan and an Employee Stock Option Agreement dated May 4, 2026. These governing documents define vesting, termination conditions, and other key terms for the compensation award.